Cargando…
In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and drug screening
The human ClC-Kb channel plays a key role in exporting chloride ions from the cytosol and is known to be involved in Bartter syndrome type 3 when its permeation capacity is decreased. The ClC-Kb channel has been recently proposed as a potential therapeutic target to treat hypertension. In order to g...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543074/ https://www.ncbi.nlm.nih.gov/pubmed/28775266 http://dx.doi.org/10.1038/s41598-017-07794-5 |
_version_ | 1783255083296751616 |
---|---|
author | Louet, Maxime Bitam, Sara Bakouh, Naziha Bignon, Yohan Planelles, Gabrielle Lagorce, David Miteva, Maria A. Eladari, Dominique Teulon, Jacques Villoutreix, Bruno O. |
author_facet | Louet, Maxime Bitam, Sara Bakouh, Naziha Bignon, Yohan Planelles, Gabrielle Lagorce, David Miteva, Maria A. Eladari, Dominique Teulon, Jacques Villoutreix, Bruno O. |
author_sort | Louet, Maxime |
collection | PubMed |
description | The human ClC-Kb channel plays a key role in exporting chloride ions from the cytosol and is known to be involved in Bartter syndrome type 3 when its permeation capacity is decreased. The ClC-Kb channel has been recently proposed as a potential therapeutic target to treat hypertension. In order to gain new insights into the sequence-structure-function relationships of this channel, to investigate possible impacts of amino-acid substitutions, and to design novel inhibitors, we first built a structural model of the human ClC-Kb channel using comparative modeling strategies. We combined in silico and in vitro techniques to analyze amino acids involved in the chloride ion pathway as well as to rationalize the possible role of several clinically observed mutations leading to the Bartter syndrome type 3. Virtual screening and drug repositioning computations were then carried out. We identified six novel molecules, including 2 approved drugs, diflusinal and loperamide, with Kd values in the low micromolar range, that block the human ClC-Kb channel and that could be used as starting point to design novel chemical probes for this potential therapeutic target. |
format | Online Article Text |
id | pubmed-5543074 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-55430742017-08-07 In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and drug screening Louet, Maxime Bitam, Sara Bakouh, Naziha Bignon, Yohan Planelles, Gabrielle Lagorce, David Miteva, Maria A. Eladari, Dominique Teulon, Jacques Villoutreix, Bruno O. Sci Rep Article The human ClC-Kb channel plays a key role in exporting chloride ions from the cytosol and is known to be involved in Bartter syndrome type 3 when its permeation capacity is decreased. The ClC-Kb channel has been recently proposed as a potential therapeutic target to treat hypertension. In order to gain new insights into the sequence-structure-function relationships of this channel, to investigate possible impacts of amino-acid substitutions, and to design novel inhibitors, we first built a structural model of the human ClC-Kb channel using comparative modeling strategies. We combined in silico and in vitro techniques to analyze amino acids involved in the chloride ion pathway as well as to rationalize the possible role of several clinically observed mutations leading to the Bartter syndrome type 3. Virtual screening and drug repositioning computations were then carried out. We identified six novel molecules, including 2 approved drugs, diflusinal and loperamide, with Kd values in the low micromolar range, that block the human ClC-Kb channel and that could be used as starting point to design novel chemical probes for this potential therapeutic target. Nature Publishing Group UK 2017-08-03 /pmc/articles/PMC5543074/ /pubmed/28775266 http://dx.doi.org/10.1038/s41598-017-07794-5 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Louet, Maxime Bitam, Sara Bakouh, Naziha Bignon, Yohan Planelles, Gabrielle Lagorce, David Miteva, Maria A. Eladari, Dominique Teulon, Jacques Villoutreix, Bruno O. In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and drug screening |
title | In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and drug screening |
title_full | In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and drug screening |
title_fullStr | In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and drug screening |
title_full_unstemmed | In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and drug screening |
title_short | In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and drug screening |
title_sort | in silico model of the human clc-kb chloride channel: pore mapping, biostructural pathology and drug screening |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543074/ https://www.ncbi.nlm.nih.gov/pubmed/28775266 http://dx.doi.org/10.1038/s41598-017-07794-5 |
work_keys_str_mv | AT louetmaxime insilicomodelofthehumanclckbchloridechannelporemappingbiostructuralpathologyanddrugscreening AT bitamsara insilicomodelofthehumanclckbchloridechannelporemappingbiostructuralpathologyanddrugscreening AT bakouhnaziha insilicomodelofthehumanclckbchloridechannelporemappingbiostructuralpathologyanddrugscreening AT bignonyohan insilicomodelofthehumanclckbchloridechannelporemappingbiostructuralpathologyanddrugscreening AT planellesgabrielle insilicomodelofthehumanclckbchloridechannelporemappingbiostructuralpathologyanddrugscreening AT lagorcedavid insilicomodelofthehumanclckbchloridechannelporemappingbiostructuralpathologyanddrugscreening AT mitevamariaa insilicomodelofthehumanclckbchloridechannelporemappingbiostructuralpathologyanddrugscreening AT eladaridominique insilicomodelofthehumanclckbchloridechannelporemappingbiostructuralpathologyanddrugscreening AT teulonjacques insilicomodelofthehumanclckbchloridechannelporemappingbiostructuralpathologyanddrugscreening AT villoutreixbrunoo insilicomodelofthehumanclckbchloridechannelporemappingbiostructuralpathologyanddrugscreening |